Blockchain Registration Transaction Record

Annovis Bio (ANVS) Advances Lead Drug Candidate for Alzheimer’s and Parkinson’s Diseases with FDA Clearance for Phase 3 Trials

Annovis Bio (ANVS) provides update on lead drug candidate buntanetap for Alzheimer’s and Parkinson’s diseases, securing FDA clearance for Phase 3 trials. Significant progress made with new funds, patents, and team expansion to support clinical trials.

This news matters as Annovis Bio's progress in developing buntanetap offers hope for patients with neurodegenerative diseases like AD and PD. The FDA clearance for Phase 3 studies signifies a significant milestone in the company's efforts to provide potential symptomatic relief and disease-modifying therapies.